Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin

Increased Dosage of MRA Improves BP and Urinary Albumin Excretion in Primary Aldosteronism With Suppressed Plasma Renin

Abstract Purpose Excessive aldosterone secretion causes a high risk of cardio-cerebrovascular events. Mineralocorticoid receptor antagonist (MRA) is 1 of the treatment strategies for primary aldosteronism (PA). However, current MRA treatment is insufficient because MRA-treated patients with suppress...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the Endocrine Society 2022-01, Vol.6 (1), p.bvab174-bvab174
Hauptverfasser: Saiki, Aya, Otsuki, Michio, Tamada, Daisuke, Kitamura, Tetsuhiro, Mukai, Kosuke, Yamamoto, Koichi, Shimomura, Iichiro
Format: Artikel
Sprache:eng
Schlagworte:
Albumin
Aldosterone
Blood pressure
Cardiovascular diseases
Clinical
Corticosteroids
Hyperaldosteronism
Medical colleges
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Abstract Purpose Excessive aldosterone secretion causes a high risk of cardio-cerebrovascular events. Mineralocorticoid receptor antagonist (MRA) is 1 of the treatment strategies for primary aldosteronism (PA). However, current MRA treatment is insufficient because MRA-treated patients with suppressed plasma renin activity (PRA) 
ISSN:2472-1972
2472-1972
DOI:10.1210/jendso/bvab174